Public hospital in Thessaloniki providing clinical research infrastructure for elderly care and digital palliative oncology studies.
Papanikolaou General Hospital is a major public clinical institution in Thessaloniki, northern Greece, providing acute and specialist hospital care across a wide range of medical disciplines. In EU research, the hospital contributes its clinical infrastructure: real patient populations, hospital-based clinical staff, and the ability to run and validate studies in a live healthcare environment. Their H2020 work spans two adjacent areas — technology-assisted independent living for elderly patients, and digital tools for palliative care in adults and children with cancer. Their value in research consortia is as a clinical validation site: they give technology developers and academic researchers access to the actual patients and care pathways that the interventions are designed for.
Participated as a third party in MyPal (2019–2022), a project focused on patient-reported outcome systems and early palliative care for adults and children with solid tumors and haematologic malignancies.
MyPal specifically targeted patient empowerment through digital health tools and structured satisfaction-with-care measurement, indicating hands-on exposure to PRO system deployment in a hospital setting.
Joined the IN LIFE consortium (2015–2018) as a full participant, contributing clinical context to a project developing independent living support functions for elderly people.
Both projects (IN LIFE and MyPal) required real-world clinical study environments; the hospital's participation in both signals a consistent role as a site for patient-facing research and clinical data collection.
In their first H2020 project (IN LIFE, 2015–2018), the hospital contributed to research on assistive technologies for elderly people living independently — a broad, technology-in-care topic with no documented clinical specialisation at the time. By their second project (MyPal, 2019–2022), the focus had narrowed sharply into oncology and palliative care, with a clear emphasis on digital health tools, patient-reported outcomes, and measuring quality of life and satisfaction in cancer patients. The shift suggests the hospital is moving from general participation in health technology projects toward a more defined identity as a clinical site for patient-centred cancer care research.
The hospital appears to be consolidating around oncology and digital patient-reported outcomes — making them a credible clinical partner for future projects in cancer care quality, end-of-life support, or patient empowerment technology.
Papanikolaou has never led an H2020 project — all participation has been as a partner or third party, which is typical for clinical institutions whose primary value is patient access and care-pathway expertise rather than project management or technology development. They joined large, multi-partner consortia (35 partners across 12 countries from just two projects), suggesting they are comfortable operating inside complex, coordinator-led research structures. Working with them likely means engaging a hospital administration for ethics approval and patient recruitment, rather than a dedicated research office with rapid response capacity.
Despite only two H2020 projects, the hospital has connected with 35 unique partners across 12 countries — a sign that both consortia were large, pan-European collaborations. There is no evidence of a tight recurring network; their connections appear broad and project-driven rather than built on repeated bilateral partnerships.
As one of the larger public hospitals in northern Greece, Papanikolaou provides access to a substantial and demographically distinct patient population — useful for studies that need geographic and ethnic diversity within European clinical trials. Their combination of oncology and elderly care experience is relatively rare among Greek public hospitals in the H2020 dataset, making them a plausible clinical site for projects that need southern European patient cohorts in these two domains. Their institutional standing as a named public hospital also provides the regulatory and ethical credibility that research consortia require from clinical partners.
